SAN FRANCISCO--(BUSINESS WIRE)-- AliveCor, the developer of a breakthrough mobile electrocardiogram (ECG) device, today announced that Judy Wade has been appointed President, Chief Executive Officer and a Director. Ms. Wade is responsible for building the organization, developing the strategic roadmap for AliveCor’s unique technology capabilities, and ensuring successful commercialization and regulatory clearance for AliveCor’s products. Upon 510(k) marketing clearance from the US Food and Drug Administration (FDA), the company plans to launch its ECG device for iPhone in the human health market as well as in the animal health markets.
“I am delighted to be a part of AliveCor and help realize the vision created by Dr. David Albert and his co-founders Bruce Satchwell and Kim Barnett,” commented Ms. Wade. “Our innovative technology’s transformative potential for providing physicians, healthcare providers and their patients with accessible and cost-effective healthcare was the reason for my joining the team.”
Prior to AliveCor, Judy was the President and CEO of Hands-On Entertainment, a leading developer of mobile and social applications. Before that, she was the Vice President of Strategy and Emerging Business at Linden Lab and an Entrepreneur-in-Residence at Kapor Enterprises Inc., the investment company of Mitch Kapor, a pioneer in the personal computing industry. Judy Wade was also a Partner at McKinsey & Company where she worked in McKinsey’s New York, Johannesburg (as an original founder), and San Francisco offices.
"The Board is thrilled to have attracted someone with the skills and experience of Judy to lead AliveCor,” said G. Steven Burrill, CEO of Burrill & Company, Chairman of the Board of Directors of AliveCor and an investor in AliveCor. “Judy brings invaluable international strategy and go-to-market experience, and immediate expertise in mobile applications. This knowledge will be essential as we introduce our products globally to medical and veterinary professionals and, eventually to consumers."
AliveCor aims to provide medical professionals, patients, and consumers worldwide with mobile-powered devices, data, and analysis to identify, prevent, and manage life-altering diseases from anywhere in the world. As a first offering, AliveCor has developed a clinical-quality, low-cost mobile ECG device, which enables patients to monitor their heart health anywhere, at any time, and provides physicians with an additional heart health assessment tool. AliveCor’s mobile ECG device is designed to work in conjunction with a variety of mobile platforms, including iPhone, iPad, and Android devices.
In 2011, AliveCor raised $3.3M in a Series A financing with Burrill & Company, Qualcomm Incorporated, acting through its venture investment arm, Qualcomm Ventures, and the Oklahoma Life Science Fund. The company’s mobile ECG device has been used in clinical studies at the University of Oklahoma Health Sciences Center and the USC Center for Body Computing. AliveCor is seeking US 510(k) marketing clearance of its mobile ECG device for the iPhone. For more information, please visit www.alivecor.com or e-mail firstname.lastname@example.org.
AliveCor, the AliveCor logo, and all other AliveCor product names and slogans are trademarks or registered trademarks of AliveUSA, Inc. dba AliveCor in the United States and/or other countries. All other company names and marks mentioned in this release are trademarks of their respective owners.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50304627&lang=en
Amanda Murphy, 978-745-4200 x107
Donna LaVoie, 978-745-4200 x103